

Levitsky A. P., Pavlenko K. V., Selivanska I. O., Lapinska A. P. Enzymatic method for determining in vivo the mineralizing efficiency of osteoprotective drugs. Journal of Education, Health and Sport. 2026;87:68087. eISSN 2391-8306.  
<https://dx.doi.org/10.12775/JEHS.2026.87.68087>  
<https://apcz.umk.pl/JEHS/article/view/68087>  
<https://zenodo.org/records/18202641>

The journal has had 40 points in Minister of Science and Higher Education of Poland parametric evaluation. Annex to the announcement of the Minister of Education and Science of 05.01.2024 No. 32318. Has a Journal's Unique Identifier: 201159. Scientific disciplines assigned: Physical culture sciences (Field of medical and health sciences); Health Sciences (Field of medical and health sciences). Punkty Ministerialne 40 punktów. Załącznik do komunikatu Ministra Nauki i Szkolnictwa Wyższego z dnia 05.01.2024 Lp. 32318. Posiada Unikatowy Identyfikator Czasopisma: 201159. Przypisane dyscypliny naukowe: Nauki o kulturze fizycznej (Dziedzina nauk medycznych i nauk o zdrowiu); Nauki o zdrowiu (Dziedzina nauk medycznych i nauk o zdrowiu). © The Authors 2026; This article is published with open access at Licensee Open Journal Systems of Nicolaus Copernicus University in Toruń, Poland. Open Access. This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. This is an open access article licensed under the terms of the Creative Commons Attribution Non commercial license Share alike. (<http://creativecommons.org/licenses/by-nc-sa/4.0/>) which permits unrestricted, non commercial use, distribution and reproduction in any medium, provided the work is properly cited. The authors declare that there is no conflict of interests regarding the publication of this paper. Received: 14.12.2025. Revised: 30.12.2025. Accepted: 30.12.2025. Published: 09.01.2026.

UDC 577.07.003+611.018.4

## **ENZYMATIC METHOD FOR DETERMINING IN VIVO THE MINERALIZING EFFICIENCY OF OSTEOPROTECTIVE DRUGS**

**A. P. Levitsky<sup>1</sup>, K. V. Pavlenko<sup>2</sup>, I. O. Selivanska<sup>2</sup>, A. P. Lapinska<sup>1</sup>**

**<sup>1</sup>Odessa National Technological University, Odessa, Ukraine**

**<sup>2</sup>Odessa National Medical University, Odessa, Ukraine**

### **Abstract**

For screening osteoprotectors, it is proposed to investigate the mineralizing activity of rat bone tissue (femur, jaws, teeth) in which experimental osteoporosis was reproduced (stress, inadequate nutrition, dysmetabolic syndrome). It is proposed to determine the mineralizing activity by the ratio of alkaline (ALP) and acid (AP) phosphatase activity in bone tissue.

It is proposed to determine in vivo the mineralizing efficiency of the drug by the percentage increase in mineralizing activity per dose of the drug in mg/kg of live weight.

Of the three osteoprotectors studied (EkSoVit, quercetin and ascorbic acid), quercetin was the most effective, and ascorbic acid was the least effective.

**Keywords:** osteogenesis, mineralization, osteoprotectors.

The main mineral component of bone tissue is hydroxyapatite, which is formed by the interaction of inorganic phosphate and calcium salts [1-3]. Inorganic phosphate is a product of hydrolysis of organic phosphorus-containing compounds (glucose phosphate, glycerophosphate,

phosphatidic acid) under the influence of phosphatase enzymes: alkaline (optimum action pH 10.5) and acidic (optimum action pH 4.8) [4].

Alkaline phosphatase (ALP) is synthesized in osteoblasts and osteocytes and secreted together with the protein procollagen. Acid phosphatase (AP) is synthesized K in osteoclasts and secreted together with acid [5, 6]. If ALP causes the formation of hydroxyapatite, then AP promotes its hydrolysis. The final result of the accumulation of hydroxyapatite in bone tissue depends on the optimal ALP/AP ratio [7]. In the first period of life (up to 50 years), this ratio increases, and after 50 years begins to decrease [8], and the level of the ALP/AP ratio is significantly higher in men than in women [8].

We have proposed to call the ratio of ALP/AP the mineralization index (MI) [7, 8]. The mineralization index decreases not only in old age, but also from taking corticosteroids [9, 10], omeprazole [11], in diabetes mellitus [8], when consuming fats with a high content of linoleic acid [12], in various intoxications [13] and, as a rule, in osteoporosis [13].

A large number of drugs (calcium salts, hormonal drugs, protein products, plant extracts) have been proposed for the prevention and treatment of osteoporosis [14, 15].

Recently, antioxidant drugs have attracted great interest [16].

The aim of our work was to develop a method for determining *in vivo* the mineralizing efficacy of various osteoprotective drugs, taking into account their effect on the mineralizing index MI.

From a practical perspective, the best biological object for solving this problem is rats, in which it is possible to study the effect of osteoprotective drugs on the level of MI in various bones: teeth, jaws, femurs, vertebrae.

To carry out the procedure for determining mineralizing efficiency (ME), it is necessary to conduct a study of the mineralizing index MI in at least 3 groups of rats using a certain pathogenic factor (stress, nutrition, intoxication, etc.).

One group of rats should be intact, the second group – experimental with pathology and the third – with pathology, but additionally with the use of osteoprotector. As a result, 3 MI indicators will be obtained: MI<sub>n</sub> (group I), MI<sub>e</sub> (group II) and MI<sub>p</sub> (group III). The calculation of mineralizing efficiency (ME) is carried out by the formula:

$$ME = \frac{(MI_p - MI_e) \cdot 100}{(MI_n - MI_e) \cdot C},$$

where C is the dose of the drug in mg/kg of live weight;

MI<sub>n</sub> – indicator of the intact group of rats;

MI<sub>e</sub> – indicator of the group with pathology but without the drug;

MI<sub>p</sub> – group with stress + drug.

A specific example of the definition of ME.

This study used 20 white rats (males, live weight  $220\pm10$  g), divided into 5 groups: Group I – normal (intact), Group II – stress + oral applications of gel without osteoprotector; Group III – stress + gel with EkSoVit (dose 13.6 mg/kg); Group IV – stress + oral applications of gel with quercetin (dose 6.82 mg/kg) and Group V – stress + oral applications of gel with ascorbic acid (dose 6.82 mg/kg).

Stress was reproduced by exposing rats to a temperature of  $-20$  °C for 30 minutes.

After euthanasia of the animals, the femur was isolated, in the homogenate of which the activity of ALP and AP [4] was determined and the mineralization index MI was calculated based on the ratio of ALP/AP [7].

The results of determining the mineralization index MI and mineralization efficiency ME are presented in the table.

Table. Mineralizing efficacy of osteoprotectors

№№	Group	Dose of drug mg/kg	MI	ME $\Delta MI/mg/kg$
1	Norm (intact )	0	$9,80\pm0,37$	–
2	Stress (study group)	0	$5,27\pm0,25$ $p<0,01$	–
3	Stress + EkSoVit drug	13,6	$9,83\pm0,70$ $p=1; p_1<0,01$	$7,35\pm0,56$
4	Stress + Quercetin drug	6,82	$8,31\pm0,74$ $p>0,05; p_1<0,05$	$9,86\pm0,60$
5	Stress + Ascorbic acid drug	6,82	$6,93\pm0,71$ $p<0,05; p_1>0,05$	$5,37\pm0,49$

Notes: p – compared to group 1;  $p_1$  – compared to group 2.

As can be seen from the presented data, the most effective osteoprotector of the three studied was quercetin, and the less effective was the ascorbic acid preparation.

### Conclusions

1. A method for determining the mineralizing efficiency of an osteoprotector is proposed, taking into account the increase in MI in percent per 1 mg/kg of the drug.
2. Of the three drugs, quercetin was the most effective and the less effective was ascorbic acid.

## **Author Contributions**

The authors agree to equal distribution of partial participation.

## **Funding**

This study received external funding.

## **Informed Consent Statement**

Informed consent was obtained from all subjects who participated in the study.

## **Data Availability Statement**

All information is in the public domain and specific graphic data can be obtained upon request from the corresponding senior author.

## **Conflicts of Interest**

The authors declare that they have no conflicts of interest.

## **Acknowledgments**

The study was carried out by the authors themselves without any outside assistance.

## **References**

1. Rinaldo Florencio-Silva, Gisela Rodrigues da Silva Sasso, Estela Sasso-Cerri, Manuel Jesus Simões, Paulo Sérgio Cerri. Biology of Bone Tissue: Structure, Function, and Factors That Influence Bone Cells. *Biomed Res Int.* 2015;2015:421746. doi: 10.1155/2015/421746.
2. Blumsohn A, Eastell R (1997) The performance and utility of biochemical markers of bone turnover: do we know enough to use them in clinical practice? *Ann Clin Biochem* 1997;34(5):449-459.
3. Macdonald H. M., New S. A., Golden M. H. N., Campbell M. K., Reid D. M. Nutritional associations with bone loss during the menopausal transition: Evidence of a beneficial effect of calcium, alcohol, and fruit and vegetable nutrients and of a detrimental effect of fatty acids. *Am. J. Clin. Nutr.* 2004;79(1): 155-165.
4. Levitsky A. P., Makarenko O. A., Denga O. V., Sukmanskiy O.I., Podorozhnaya R. P., Rossachanova L. N., Khodakov I. V., Zelenina Yu.V. The experimental methods of the study of osteogenesis stimulators. Kiev, GFK, 2005:50. (in Russian)
5. Bunker V.W. The role of nutrition in osteoporosis. *Br. J. Biomed. Sci.* 1994;51 (3):228-240.
6. Korzh N. A., Deduh N. V. Risk factors for osteoporosis. International medical journal. 2007;2:70-74. (in Russian)
7. Levitsky A. P., Makarenko O. A., Khodakov I. V., Zelenina Yu. V. The enzymatic method of the estimation of the state of osseous tissue. *Odessa Medical Journal.* 2006;3:17-21. (in Ukrainian)

8. Levitsky A. P., Selivanskaya I. O., Tishchenko T. L., Stupak O. P. Mineralizing activity of periodontal bone tissue of rats with experimental diabetes. *Journal of Education, Health and Sport.* 2023;42(1):115-123. <https://apcz.umk.pl/JEHS/article/view/45435>
9. Elbahnasawy A. S., Valeeva E. R., El-Sayed E. M., Stepanova N. V. Protective effect of dietary oils containing omega-3 fatty acids against glucocorticoid-induced osteoporosis. *J Nutr Health.* 2019;52(4):323-331. <https://doi.org/10.4163/jnh.2019.52.4.323>
10. Mashhenko I. S., Konovalova D. A. Osteoporotic activity in the alveolar bone of patients with bronchial asthma receiving corticosteroid therapy. *Modern Dentistry.* 2002;1:36-38. (in Russian)
11. Ahmed Al Subaie, Elham Emami, Iskandar Tamimi, Marco Laurenti, Hazem Eimar, Mohamed-Nur Abdallah, Faleh Tamimi. Systemic administration of omeprazole interferes with bone healing and implant osseointegration: an in vivo study on rat tibiae. *J Clin Periodontol.* 2016;43(2):193-203. doi: 10.1111/jcpe.12506. Epub 2016 Feb 23.
12. Levitsky A. P., Pupin T. I., Selivanskaya I. O., Lapinskaya A. P., Markov A. V. Reduction of mineralizing activity of periodontal bone tissue in rats with consumption of ordinary sunflower oil. *Journal of Education, Health and Sport.* 2022;12(12):323-330. DOI <http://dx.doi.org/10.12775/JEHS.2022.12.12.049>
13. Charles T Price, Joshua R Langford, Frank A Liporace. Essential Nutrients for Bone Health and a Review of their Availability in the Average North American Diet. *Open Orthop J.* 2012;6:143-9. doi: 10.2174/1874325001206010143
14. Silvina Levis, Violet S Lagari. The role of diet in osteoporosis prevention and management. *Curr Osteoporos Rep.* 2012;10(4):296-302. doi: 10.1007/s11914-012-0119-y.
15. Sandra Maria Sacco, Marie-Noëlle Horcajada, Elizabeth Offord. Phytonutrients for bone health during ageing. *Br J Clin Pharmacol.* 2013;75(3):697-707. doi: 10.1111/bcp.12033.
16. Makarenko O. A. Antioxidant mechanisms of action of flavonoids in bone tissue. *Odessa Medical Journal.* 2010;5(121):17-20. (in Ukrainian)